🏃 Grab this Black Friday offer early. Get up to 55% off InvestingPro now!CLAIM SALE

Teva completes enrollment for schizophrenia drug trial

EditorRachael Rajan
Published 01/10/2024, 02:32 AM
© Reuters
TEVA
-
MEDCL
-

MONTPELLIER, France - Teva Pharmaceutical Industries (NYSE:TEVA) Ltd. has announced the completion of patient enrollment for its Phase 3 trial of mdc-TJK, a potential new treatment for schizophrenia. The trial has registered 640 participants across the European Union and the United States, with results anticipated in the latter half of 2024.

The drug, mdc-TJK (TEV-44749), is a once-monthly subcutaneous injection and represents an atypical antipsychotic olanzapine formulation. It is being developed as a long-acting option that could potentially be the first of its kind to offer a favorable safety profile. This development comes as a significant step, especially considering the current long-acting injectable (LAI) olanzapine carries an FDA black box warning for Post injection Delirium/Sedation Syndrome (PDSS), which has limited its use.

Teva is leading the development and will handle the global commercialization of this olanzapine LAI. MedinCell, a biopharmaceutical company specializing in long-acting injectable drugs, stands to receive up to $117 million in development and commercial milestones for mdc-TJK, along with royalties on net sales.

MedinCell's proprietary BEPO® technology, which controls drug delivery over extended periods, has already seen success with the FDA approval of UZEDY™, a treatment for schizophrenia, in April 2023. UZEDY™ is now available in the United States through Teva, under the licensed name SteadyTeq™.

The collaboration between Teva and MedinCell underscores a commitment to advancing treatment options for schizophrenia, a chronic brain disorder that affects about 1% of the population worldwide. The completion of enrollment for the mdc-TJK trial marks a milestone in their joint efforts to enhance therapeutic effectiveness and patient compliance.

This report is based on a press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.